Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of SEA-CD70 in Myeloid Malignancies
jRCT2021250017Phase 1Active, not recruiting
- Sponsor
- Pfizer
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label trial of SEA-CD70 in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) (7 arms), sponsored by Pfizer. Primary endpoints: Number of participants with adverse events, Number of participants with laboratory abnormalities and 1 more. Started Oct 2025; status: active, not recruiting.
02
Drugs
SEA-CD70
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2021250017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021250017.